Review



mouse egfl7  (Sino Biological)


Bioz Verified Symbol Sino Biological is a verified supplier
Bioz Manufacturer Symbol Sino Biological manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 92
      Buy from Supplier

    Structured Review

    Sino Biological mouse egfl7
    Mouse Egfl7, supplied by Sino Biological, used in various techniques. Bioz Stars score: 92/100, based on 2 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mouse egfl7/product/Sino Biological
    Average 92 stars, based on 2 article reviews
    mouse egfl7 - by Bioz Stars, 2026-02
    92/100 stars

    Images



    Similar Products

    mouse egfl7  (Sino Biological)
    92
    Sino Biological mouse egfl7
    Mouse Egfl7, supplied by Sino Biological, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mouse egfl7/product/Sino Biological
    Average 92 stars, based on 1 article reviews
    mouse egfl7 - by Bioz Stars, 2026-02
    92/100 stars
    		  Buy from Supplier
    goat anti mouse egfl7  (R&D Systems)
    90
    R&D Systems goat anti mouse egfl7
    <t>EGFL7/miR-126</t> is a target of GATA2. (A) miR-126 was expressed in the dorsal aorta and in the LVV-ECs (arrow) of control embryos. (B) Expression of miR-126 was downregulated in the LVV-ECs (arrow) of E12.0 Lyve1-Cre;Gata2 f/f embryos. However, no obvious difference in miR-126 expression was observed in the dorsal aorta of mutants. Red dashed line indicates the endothelial layer of the lymph sac. (C) EGFL7 was expressed in the mesenteric arteries, veins and lymphatic vessels of E18.5 control embryos. The strongest expression of EGFL7 was observed in LVs (arrow). (D) Expression of EGFL7 was dramatically downregulated in the mesenteric lymphatic vessels of mice lacking GATA2 in LECs. Also, notice the absence of LVs in the mutant. (E) ChIP revealed that GATA2 strongly associates with the promoter element of the EGFL7/miR-126 locus. The top gel shows PCR performed using primers flanking the GATA2-binding site. The lower gel shows PCR performed using primers for a non-specific site. The graph compares qPCR signals generated by primers flanking the GATA2-binding site. A, artery; DA, dorsal aorta; L, lymphatic vessel; LS, lymph sac; V, vein. (A,B) n =3 embryos and 6 LVV complexes per genotype; (C,D) n =3 embryos per genotype; (E) n =4. ** P <0.01. Scale bars: 250 μm (A,B); 200 μm (C,D).
    Goat Anti Mouse Egfl7, supplied by R&D Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/goat anti mouse egfl7/product/R&D Systems
    Average 90 stars, based on 1 article reviews
    goat anti mouse egfl7 - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    mouse anti-egfl7 (ls-c153302)  (Absolute Biotech Inc)
    90
    Absolute Biotech Inc mouse anti-egfl7 (ls-c153302)
    <t>EGFL7/miR-126</t> is a target of GATA2. (A) miR-126 was expressed in the dorsal aorta and in the LVV-ECs (arrow) of control embryos. (B) Expression of miR-126 was downregulated in the LVV-ECs (arrow) of E12.0 Lyve1-Cre;Gata2 f/f embryos. However, no obvious difference in miR-126 expression was observed in the dorsal aorta of mutants. Red dashed line indicates the endothelial layer of the lymph sac. (C) EGFL7 was expressed in the mesenteric arteries, veins and lymphatic vessels of E18.5 control embryos. The strongest expression of EGFL7 was observed in LVs (arrow). (D) Expression of EGFL7 was dramatically downregulated in the mesenteric lymphatic vessels of mice lacking GATA2 in LECs. Also, notice the absence of LVs in the mutant. (E) ChIP revealed that GATA2 strongly associates with the promoter element of the EGFL7/miR-126 locus. The top gel shows PCR performed using primers flanking the GATA2-binding site. The lower gel shows PCR performed using primers for a non-specific site. The graph compares qPCR signals generated by primers flanking the GATA2-binding site. A, artery; DA, dorsal aorta; L, lymphatic vessel; LS, lymph sac; V, vein. (A,B) n =3 embryos and 6 LVV complexes per genotype; (C,D) n =3 embryos per genotype; (E) n =4. ** P <0.01. Scale bars: 250 μm (A,B); 200 μm (C,D).
    Mouse Anti Egfl7 (Ls C153302), supplied by Absolute Biotech Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mouse anti-egfl7 (ls-c153302)/product/Absolute Biotech Inc
    Average 90 stars, based on 1 article reviews
    mouse anti-egfl7 (ls-c153302) - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    goat polyclonal anti mouse egfl7 r 12 antibody  (Santa Cruz Biotechnology)
    94
    Santa Cruz Biotechnology goat polyclonal anti mouse egfl7 r 12 antibody
    <t>EGFL7/miR-126</t> is a target of GATA2. (A) miR-126 was expressed in the dorsal aorta and in the LVV-ECs (arrow) of control embryos. (B) Expression of miR-126 was downregulated in the LVV-ECs (arrow) of E12.0 Lyve1-Cre;Gata2 f/f embryos. However, no obvious difference in miR-126 expression was observed in the dorsal aorta of mutants. Red dashed line indicates the endothelial layer of the lymph sac. (C) EGFL7 was expressed in the mesenteric arteries, veins and lymphatic vessels of E18.5 control embryos. The strongest expression of EGFL7 was observed in LVs (arrow). (D) Expression of EGFL7 was dramatically downregulated in the mesenteric lymphatic vessels of mice lacking GATA2 in LECs. Also, notice the absence of LVs in the mutant. (E) ChIP revealed that GATA2 strongly associates with the promoter element of the EGFL7/miR-126 locus. The top gel shows PCR performed using primers flanking the GATA2-binding site. The lower gel shows PCR performed using primers for a non-specific site. The graph compares qPCR signals generated by primers flanking the GATA2-binding site. A, artery; DA, dorsal aorta; L, lymphatic vessel; LS, lymph sac; V, vein. (A,B) n =3 embryos and 6 LVV complexes per genotype; (C,D) n =3 embryos per genotype; (E) n =4. ** P <0.01. Scale bars: 250 μm (A,B); 200 μm (C,D).
    Goat Polyclonal Anti Mouse Egfl7 R 12 Antibody, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/goat polyclonal anti mouse egfl7 r 12 antibody/product/Santa Cruz Biotechnology
    Average 94 stars, based on 1 article reviews
    goat polyclonal anti mouse egfl7 r 12 antibody - by Bioz Stars, 2026-02
    94/100 stars
    		  Buy from Supplier
    mouse monoclonal anti egfl7 antibody  (Santa Cruz Biotechnology)
    93
    Santa Cruz Biotechnology mouse monoclonal anti egfl7 antibody
    <t>EGFL7/miR-126</t> is a target of GATA2. (A) miR-126 was expressed in the dorsal aorta and in the LVV-ECs (arrow) of control embryos. (B) Expression of miR-126 was downregulated in the LVV-ECs (arrow) of E12.0 Lyve1-Cre;Gata2 f/f embryos. However, no obvious difference in miR-126 expression was observed in the dorsal aorta of mutants. Red dashed line indicates the endothelial layer of the lymph sac. (C) EGFL7 was expressed in the mesenteric arteries, veins and lymphatic vessels of E18.5 control embryos. The strongest expression of EGFL7 was observed in LVs (arrow). (D) Expression of EGFL7 was dramatically downregulated in the mesenteric lymphatic vessels of mice lacking GATA2 in LECs. Also, notice the absence of LVs in the mutant. (E) ChIP revealed that GATA2 strongly associates with the promoter element of the EGFL7/miR-126 locus. The top gel shows PCR performed using primers flanking the GATA2-binding site. The lower gel shows PCR performed using primers for a non-specific site. The graph compares qPCR signals generated by primers flanking the GATA2-binding site. A, artery; DA, dorsal aorta; L, lymphatic vessel; LS, lymph sac; V, vein. (A,B) n =3 embryos and 6 LVV complexes per genotype; (C,D) n =3 embryos per genotype; (E) n =4. ** P <0.01. Scale bars: 250 μm (A,B); 200 μm (C,D).
    Mouse Monoclonal Anti Egfl7 Antibody, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mouse monoclonal anti egfl7 antibody/product/Santa Cruz Biotechnology
    Average 93 stars, based on 1 article reviews
    mouse monoclonal anti egfl7 antibody - by Bioz Stars, 2026-02
    93/100 stars
    		  Buy from Supplier
    anti egfl7  (R&D Systems)
    90
    R&D Systems anti egfl7
    <t>EGFL7/miR-126</t> is a target of GATA2. (A) miR-126 was expressed in the dorsal aorta and in the LVV-ECs (arrow) of control embryos. (B) Expression of miR-126 was downregulated in the LVV-ECs (arrow) of E12.0 Lyve1-Cre;Gata2 f/f embryos. However, no obvious difference in miR-126 expression was observed in the dorsal aorta of mutants. Red dashed line indicates the endothelial layer of the lymph sac. (C) EGFL7 was expressed in the mesenteric arteries, veins and lymphatic vessels of E18.5 control embryos. The strongest expression of EGFL7 was observed in LVs (arrow). (D) Expression of EGFL7 was dramatically downregulated in the mesenteric lymphatic vessels of mice lacking GATA2 in LECs. Also, notice the absence of LVs in the mutant. (E) ChIP revealed that GATA2 strongly associates with the promoter element of the EGFL7/miR-126 locus. The top gel shows PCR performed using primers flanking the GATA2-binding site. The lower gel shows PCR performed using primers for a non-specific site. The graph compares qPCR signals generated by primers flanking the GATA2-binding site. A, artery; DA, dorsal aorta; L, lymphatic vessel; LS, lymph sac; V, vein. (A,B) n =3 embryos and 6 LVV complexes per genotype; (C,D) n =3 embryos per genotype; (E) n =4. ** P <0.01. Scale bars: 250 μm (A,B); 200 μm (C,D).
    Anti Egfl7, supplied by R&D Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti egfl7/product/R&D Systems
    Average 90 stars, based on 1 article reviews
    anti egfl7 - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    EGFL7/miR-126 is a target of GATA2. (A) miR-126 was expressed in the dorsal aorta and in the LVV-ECs (arrow) of control embryos. (B) Expression of miR-126 was downregulated in the LVV-ECs (arrow) of E12.0 Lyve1-Cre;Gata2 f/f embryos. However, no obvious difference in miR-126 expression was observed in the dorsal aorta of mutants. Red dashed line indicates the endothelial layer of the lymph sac. (C) EGFL7 was expressed in the mesenteric arteries, veins and lymphatic vessels of E18.5 control embryos. The strongest expression of EGFL7 was observed in LVs (arrow). (D) Expression of EGFL7 was dramatically downregulated in the mesenteric lymphatic vessels of mice lacking GATA2 in LECs. Also, notice the absence of LVs in the mutant. (E) ChIP revealed that GATA2 strongly associates with the promoter element of the EGFL7/miR-126 locus. The top gel shows PCR performed using primers flanking the GATA2-binding site. The lower gel shows PCR performed using primers for a non-specific site. The graph compares qPCR signals generated by primers flanking the GATA2-binding site. A, artery; DA, dorsal aorta; L, lymphatic vessel; LS, lymph sac; V, vein. (A,B) n =3 embryos and 6 LVV complexes per genotype; (C,D) n =3 embryos per genotype; (E) n =4. ** P <0.01. Scale bars: 250 μm (A,B); 200 μm (C,D).

    Journal: Development (Cambridge, England)

    Article Title: GATA2 controls lymphatic endothelial cell junctional integrity and lymphovenous valve morphogenesis through miR-126

    doi: 10.1242/dev.184218

    Figure Lengend Snippet: EGFL7/miR-126 is a target of GATA2. (A) miR-126 was expressed in the dorsal aorta and in the LVV-ECs (arrow) of control embryos. (B) Expression of miR-126 was downregulated in the LVV-ECs (arrow) of E12.0 Lyve1-Cre;Gata2 f/f embryos. However, no obvious difference in miR-126 expression was observed in the dorsal aorta of mutants. Red dashed line indicates the endothelial layer of the lymph sac. (C) EGFL7 was expressed in the mesenteric arteries, veins and lymphatic vessels of E18.5 control embryos. The strongest expression of EGFL7 was observed in LVs (arrow). (D) Expression of EGFL7 was dramatically downregulated in the mesenteric lymphatic vessels of mice lacking GATA2 in LECs. Also, notice the absence of LVs in the mutant. (E) ChIP revealed that GATA2 strongly associates with the promoter element of the EGFL7/miR-126 locus. The top gel shows PCR performed using primers flanking the GATA2-binding site. The lower gel shows PCR performed using primers for a non-specific site. The graph compares qPCR signals generated by primers flanking the GATA2-binding site. A, artery; DA, dorsal aorta; L, lymphatic vessel; LS, lymph sac; V, vein. (A,B) n =3 embryos and 6 LVV complexes per genotype; (C,D) n =3 embryos per genotype; (E) n =4. ** P <0.01. Scale bars: 250 μm (A,B); 200 μm (C,D).

    Article Snippet: Primary antibodies for immunohistochemistry were: rabbit anti-PROX1 (11-002, Angiobio), goat anti-human PROX1 (AF2727, R&D Systems), sheep anti-mouse FOXC2 (AF6989, R&D Systems), goat anti-mouse VEGRF3 (AF743, R&D Systems), rat anti-mouse CD31 (553370, BD Pharmingen), goat anti-mouse ITGA9 (AF3827, R&D Systems), rat anti-mouse VE-cadherin (550548, BD Pharmingen), hamster anti-mouse PDPN (127401, Biolegend), rat anti-mouse ITGA5 (553319, BD Pharmingen), goat anti-mouse GATA2 (AF2046, R&D Systems), rabbit anti-mouse CX37 (40-4200, Life Technologies), rabbit anti-mouse LAMA5 (Ab11575, Abcam), rabbit anti-human fibronectin (ab2413, Abcam), goat anti-human ANGPT2 (AF623, R&D Systems), goat anti-mouse EGFL7 (AF3089, R&D Systems), rabbit anti-mouse CLDN5 (34-1600, Thermo Fisher Scientific), rabbit anti-mouse LYVE-1 (11-034, Angiobio).

    Techniques: Control, Expressing, Mutagenesis, Binding Assay, Generated